🟢 Summit Therapeutics is trading 5.76% up in pre-market after partner Akeso reported HARMONi-GI1 survival superiority

Summit Therapeutics is trading at $15.05 (+5.76%) after partner Akeso reported statistically significant overall-survival superiority in the Phase III HARMONi-GI1 biliary tract cancer study.

• The announcement followed additional positive ivonescimab data published in The Lancet Oncology, reinforcing investor sentiment.
• Broader technology-led risk appetite may be providing secondary support, but the primary catalyst appears company-specific.